Drug Profile
HMBD 001
Alternative Names: 10D1F; anti-HER3 antibody - Hummingbird Bioscience; HMBD-001; HMBD-001-10D1Latest Information Update: 05 Dec 2023
Price :
$50
*
At a glance
- Originator Hummingbird Bioscience
- Developer Cancer Research UK; Hummingbird Bioscience
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB-3 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Non-small cell lung cancer
- Preclinical Colorectal cancer; Prostate cancer; Squamous cell cancer
Most Recent Events
- 05 Dec 2023 Pharmacokinetic data from a phase I/II trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 23 Oct 2023 Efficacy, adverse events and PK data from phase I/II trial in Solid tumours released by Hummingbird Bioscience
- 20 Oct 2023 Preliminary adverse events data from a phase I/II trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)